Extended Treatment in Metastatic Breast Cancer With Eribulin
NCT ID: NCT02769364
Last Updated: 2023-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
45 participants
OBSERVATIONAL
2013-11-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Eribulin [Halaven] Use For the Treatment of Advanced Breast Cancer
NCT02790320
Eribulin in Brain Metastases From HER2-negative Breast Cancer
NCT03637868
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
NCT05302778
Monotherapy With Eribulin In Her2 Negative Metastatic Breast Cancer as a First Line Treatment
NCT02061085
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
NCT01240421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants treated with eribulin for at least 7 months
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Santiago de Compostela, A Coruña, Spain
Las Palmas de Gran Canarias, Gran Canaria, Spain
San Sebastián, Guipuzcoa, Spain
Barbastro, Huesca, Spain
Alcorcón, Madrid, Spain
Aravaca, Madrid, Spain
Pozuelo de Alarcón, Madrid, Spain
Pamplona, Navarre, Spain
Bilbao, Vizcaya, Spain
Badajoz, , Spain
Cáceres, , Spain
Jaén, , Spain
Lleida, , Spain
Madrid, , Spain
Málaga, , Spain
Murcia, , Spain
Ourense, , Spain
Salamanca, , Spain
Seville, , Spain
Valencia, , Spain
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OBU-SW-H-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.